Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: What to prescribe in daily clinical practice?

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 178-189

  Masclee, G M C ^a   Valkhoff, V E ^a   Van Soest, E M ^a   Schade, R ^a   Mazzaglia, G ^b   Molokhia, M ^c   Trifiro G ^a,d   Goldstein, J L ^e   Hernandez Diaz S ^f   Kuipers, E J ^a   Sturkenboom, M C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Italian College of General Practitioners   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MESSINA   (Italy)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; GASTROINTESTINAL AGENT; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; CASE CONTROL STUDY; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; ITALY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT; DRUG COMBINATION; GASTROINTESTINAL DISEASES; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879195648     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12348     Document Type: Article

References (48)

1. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
2. Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer (Guideline 106). Edinburgh: SIGN, 2008.
3. Lanza FL, Chan FK, Quigley EM,. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
4. Moens HJ, van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J, Numans ME,. Guideline 'NSAID use and the prevention of gastric damage'. Ned Tijdschr Geneeskd 2004; 148: 604-8.
5. Lai KC, Chu KM, Hui WM, et al,. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271-8.
6. Chan FK, Hung LC, Suen BY, et al,. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038-43.
7. Chan FK, Hung LC, Suen BY, et al,. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-10.
8. Simon LS, Weaver AL, Graham DY, et al,. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
9. Goldstein JL, Cryer B, Amer F, Hunt B,. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5: 1167-74.
10. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL,. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-9.
11. Schnitzer TJ, Burmester GR, Mysler E, et al,. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
12. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al,. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-8.
13. Rahme E, Barkun AN, Toubouti Y, Scalera A, Rochon S, Lelorier J,. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum 2007; 57: 748-55.
14. Targownik LE, Metge CJ, Leung S, Chateau DG,. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134: 937-44.
15. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM,. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin 2009; 25: 195-204.
16. van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ,. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 265-75.
17. van Soest EM, Valkhoff VE, Mazzaglia G, et al,. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60: 1650-9.
18. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT,. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 1337-45.
19. Valkhoff VE, van Soest EM, Mazzaglia G, et al,. Adherence to gastroprotection during cyclooxygenase-2 inhibitor use and the risk of upper gastrointestinal events: a population-based study. Arthritis Rheum 2012; 64: 2792-802.
20. Lamberts H, Wood M, Hofmans-Okkes IM,. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 330-9.
21. World Health Organization. Classification of Diseases. Available at: http://www.who.int/classifications/icd/en/(accessed March 19, 2013).
22. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Available at: http://www.whocc.no/atcddd/ (accessed March 19, 2013).
23. Hernandez-Diaz S, Rodriguez LA,. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
24. MacMahon B, Trichopoulos D,. Case-control studies. Epidemiology: Principles and Methods, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1996; 229-99.
25. Bombardier C, Laine L, Reicin A, et al,. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 20-8, 2 p following 1528.
26. Silverstein FE, Faich G, Goldstein JL, et al,. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
27. Goldstein JL, Correa P, Zhao WW, et al,. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-27.
28. Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N,. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17: 321-32.
29. Valkhoff VE, van Soest EM, Sturkenboom MC, Kuipers EJ,. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther 2010; 31: 1218-28.
30. Laine L, Connors LG, Reicin A, et al,. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92.
31. Laine L, Curtis SP, Langman M, et al,. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517-25.
32. Goldstein JL, Eisen GM, Lewis B, et al,. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 1211-22.
33. Hawkey CJ, Ell C, Simon B, et al,. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6: 536-44.
34. Maiden L, Thjodleifsson B, Seigal A, et al,. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040-5.
35. Wallace JL, Syer S, Denou E, et al,. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-22.
36. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S,. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123: 1108-15.
37. Gutthann SP, Garcia Rodriguez LA, Raiford DS,. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.
38. Hernandez-Diaz S, Rodriguez LA,. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153: 1089-93.
39. Piper JM, Ray WA, Daugherty JR, Griffin MR,. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
40. Luo JC, Shin VY, Liu ES, et al,. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 2004; 485: 275-81.
41. Luo JC, Cho CH, Ng KM, et al,. Dexamethasone inhibits tumor necrosis factor-alpha-stimulated gastric epithelial cell migration. J Chin Med Assoc 2009; 72: 509-14.
42. Fried M, Siegrist H, Frei R, et al,. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23-6.
43. Thorens J, Froehlich F, Schwizer W, et al,. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-9.
44. Parkman HP, Urbain JL, Knight LC, et al,. Effect of gastric acid suppressants on human gastric motility. Gut 1998; 42: 243-50.
45. Laine L, Maller ES, Yu C, Quan H, Simon T,. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402.
46. Alacqua M, Trifiro G, Cavagna L, et al,. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008; 59: 568-74.
47. FDA US Food and Drug Administration Public Health Advisory. Available at: http://www.fda.gov/.
48. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P,. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47-71.